Introduction
============

Colorectal carcinoma (CRC) is currently the third most prevalent cancer type worldwide. It has a complex etiology that is influenced by both environmental and genetic factors ([@b1-etm-0-0-6851]). Colorectal cancer patients in the high-risk late stage (stage II or III) are treated with adjuvant chemotherapy in combination with fluoropyrimidine monotherapy, which reduces the risk of recurrence and death by approximately 20--30% compared with fluoropyrimidine monotherapy ([@b2-etm-0-0-6851],[@b3-etm-0-0-6851]). Addition of oxaliplatin to this treatment regimen has been reported to improve disease-free survival in three individual landmark trials ([@b4-etm-0-0-6851]). Nevertheless, the side effects of this treatment have limited its application ([@b5-etm-0-0-6851]). Thus, there is an urgent requirement to explore novel therapeutic strategies against CRC. In the present study, an immunological treatment approach against CRC was investigated.

Immunization-based therapy that utilizes antigen-presenting cells (APCs) to enhance efficacy is considered to be a promising approach for the treatment of cancer ([@b6-etm-0-0-6851]). Dendritic cells (DCs) serve prominent roles in various immunization therapies by activating cytotoxic T-lymphocytes (CTLs) ([@b7-etm-0-0-6851],[@b8-etm-0-0-6851]). The key role of DCs in cell-mediated immunity serves as the basis for the development of effective DC vaccines for immunization therapies against tumors ([@b9-etm-0-0-6851],[@b10-etm-0-0-6851]). This approach may induce certain immunological responses in cancer patients with prostate cancer ([@b11-etm-0-0-6851]), lymphoma ([@b12-etm-0-0-6851]), melanoma, bladder transitional cancer ([@b13-etm-0-0-6851]) and non-small cell lung carcinoma ([@b14-etm-0-0-6851]). A sufficient number of functioning DCs that are able to activate T-cells is important for the efficacy of DC vaccines ([@b15-etm-0-0-6851]). Specific carrier proteins, cytokines, immunological adjuvants and transgenic viruses have been demonstrated to influence the immune response activation by DCs ([@b16-etm-0-0-6851]). Previous studies have reported that non-methylated cytosine-guanine (CpG) motifs may act as adjuvants for boosting tumor immunity by activating DCs. Treatment in which CpG motifs are applied may be achieved via upregulation of Th1 cytokines, soluble growth factors and primary DC surface markers ([@b17-etm-0-0-6851],[@b18-etm-0-0-6851]).

Antigen 85A (Ag85A) is involved in acid synthesis ([@b19-etm-0-0-6851]). Accumulating evidence has indicated that Ag85A may promote extensive proliferation of Th cells and the production of Th1 cytokines in mice and mycobacterium-infected humans ([@b20-etm-0-0-6851],[@b21-etm-0-0-6851]). Laboratory rats injected with plasmid DNA harboring the Ag85A gene exhibited increased generation of interleukin (IL)-2 and interferon (IFN)-γ and increased CTL activity in response to mycobacterium proteins in the Bacillus Calmette-Guérin vaccine ([@b22-etm-0-0-6851],[@b23-etm-0-0-6851]). Furthermore, injection with the Ag85A-mixed plasmid DNA vaccine protected mice from infection by *Mycobacterium tuberculosis* and resulted in stronger CTL activities ([@b24-etm-0-0-6851]). Immunization with DCs engineered with *Mycobacterium* Ag85A generated a distinct immune reaction profile, including CTL activity in response to antigenic determinants of Ag85A ([@b25-etm-0-0-6851]). Melanocytes collected from Ag85A-transfected B16-F10 mice were identified to inhibit tumorigenic effects and tumor progression ([@b26-etm-0-0-6851]). These findings demonstrate the potential use of Ag85A as an effective auxiliary agent for enhancing the immune response. However, the antitumor effects of Ag85A-mixed DCs against colorectal carcinoma remain unclear. Therefore, the present study examined whether treatment with Ag85A-transfected DC 2.4 cells could enhance the immunological response to colorectal cancer.

Materials and methods
=====================

### Mice and cells

DC 2.4 cells were collected from C57BL/6 mice and infected with GM-CSF-transfected medullary cells with myc/raf oncogenes, as previously described ([@b27-etm-0-0-6851]). CT26 colorectal carcinoma (American Type Culture Collection, Manassas, VA, USA) and DC 2.4 cell lines were cultivated in RPMI 1640 (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) at 37°C in an incubator under humid conditions with 50 ml/l CO~2~. C57BL/6 mice (n=6; male) aged 6--8 weeks (weight, 18--20 g) were obtained from the Chinese Academy of Science Shanghai Laboratory Animal Center (Shanghai, China). Animal experiments in this study were conducted in accordance with the internationally accepted principles for laboratory animal use and care. The study was approved by the Committee on the Ethics of Animal Experiments of China Medical University (Shenyang, China).

### Ag85A plasmid transfection

Cells were transfected with 1 µg Ag85A and pc-DNA3.1 (Shanghai GenePharma Co., Ltd., Shanghai, China) using Lipofectamine 2000 transfection reagent (Invitrogen; Thermo Fisher Scientific, Inc.). The pcDNA3.1+/Ag85A plasmid was incubated with Lipofectamine reagent for 20 min and subsequently added to the RPMI 1640 suspension containing DC 2.4 cells without antibiotics. The pcDNA3.1 vector without Ag85A served as the negative control. The Ag85A-DCs and mock-DCs were harvested at 48 h post-transfection.

### Quantification of Ag85A mRNA expression

Total RNA was extracted from Ag85A-DCs using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.). Reverse transcription (RT) was conducted using a Takara Prime Script RT reagent kit (Takara Biotechnology Co., Ltd., Dalian, China). Quantitative polymerase chain reaction (qPCR) was conducted using the Qiagen Quanti Tect SYBR Green PCR kit (Qiagen GmbH, Hilden, Germany) on an ABI 7300 Real-Time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.). The thermocycling conditions were as follows: 3 min at 95°C, followed by 45 cycles of 95°C for 15 sec and 60°C for 60 sec. GAPDH served as the control for qPCR amplification. Analysis was performed in triplicate, and experiments were conducted at least three times. Analysis of relative gene expression was performed using the 2^−∆∆Cq^ method ([@b28-etm-0-0-6851]). The following primers were used: GAPDH, sense, 5′-CAAAAGGGTCATCATCTCC-3′ and antisense, 5′-CCCCAGCATCAAAGGTG-3′; Ag85A, sense, 5′-CAAAGTGGTGGTGCCAACTC-3′ and antisense, 5′-CTCGCTGGTCAGGAAGGTCT-3′.

### Assessment of primary surface markers

DCs were blocked using 5% bovine serum albumin (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) at room temperature for 1 h and incubated with CD16 and 32 mAb (cat. nos. 2.4G2 and 565,502; 1:1,000; BD Biosciences, Franklin Lakes, NJ, USA) at 4°C for 15 min. Next, DCs were incubated in saturated PE-anti-MHC-II/CD80&86 mAb (cat. no. 565157; 1:1,000; BD Biosciences) at 4°C for 30 min. Cells were examined using a flow cytometer and were analyzed using FlowJo software 7.6.1 (FlowJo, LLC, Ashland, OR, USA).

### Cytokine analysis

For measurement of cytokine production, the CD3^+^ T cells (purity, \>90%) were isolated from the spleen of mice incubated with CT26 cells (1×10^6^) for 21 days, as described previously ([@b29-etm-0-0-6851]). CD3^+^ T cells were sorted via negative selection using MACS CD3 MicroBeads (Miltenyi Biotec, Inc., Cambridge, MA, USA). Subsequently, 5×10^6^ T cells were incubated with 5×10^5^ Ag85A-DCs, mimic-DCs or no DCs in CT26-lysate for 2 days at 37°C. The resulting solution was treated with Brefeldin A (10 µg/ml) for 5 h at 37°C. Cells were cultured with anti-CD4/CD8 mAbs (cat. no. 23--2615; 1:1,000; BD Biosciences) for 30 min at 4°C. The intracellular analysis was conducted using a flow cytometer (FACSCalibur; BD Biosciences). Data were analyzed using FlowJo software 7.6.1 (FlowJo, LLC, Ashland, OR, USA).

### Cell proliferation assessment

To determine cell proliferation of Ag85A-DCs, cells were treated with 25 µg/ml mitomycin C at 37°C for 30 min. Mimic-DC and non-transfected DC groups were used as controls. Cells were washed with PBS, following which cells were added to RPMI medium. Plates containing allogeneic CD3^+^ T cells (2×10^5^ cells/100 µl/well, \>90% pure), collected from C57BL/6 mice via negative selection using MACS CD3 MicroBeads were originally incubated. T-cell proliferation was measured at 1, 2 and 3 days by Cell Counting Kit 8 (CCK8) analysis. CCK8 was added to each well and cells were incubated for 4 h at 37°C. The absorbance at 570 nm was measured using a microplate reader.

### DCs pulsed with cancer cell lysate

Ag85A-DCs were incubated with tumor cell lysates through repeated freezing-thawing cycles. CT26 cells (5×10^7^/500 µl) were lysed by rapid freezing in liquid nitrogen for 10 min, followed by rapid thawing at 37°C water to dissolve the cells. This step was conducted in triplicate. Ag85A-DCs (1×10^6^ cells/ml) were cultivated in plates in RPMI-1640 with 10% fetal calf serum (Gibco; Thermo Fisher Scientific, Inc.) and 200 µl of CT26 lysate was added, to obtain 2×10^7^ cells. Cells were cultured for 2 days at 37°C and CO~2~ concentration of 50 ml/l. The CT26 lysate alone served as the negative control.

### Evaluation of cytotoxic T-lymphocytes in vitro

To verify the *in vitro* production of cancer-specific CTLs, CD3^+^ T cells were cultivated in RPMI with IL-2. Primed T-cells and CT26 tumor cells were used as effector cells and target cells, respectively. After 21 days of incubation, the target cell suspension (4×10^5^ cells/ml) was added to the plates, while the effector cells were prepared in various dilutions (effector-to-target ratio, 50:1). The supernatant was harvested after 20 h (5,000 × g; 5 min; 20°C). Cytolytic activities against CT26 cancer cells were determined using a cytotoxicity measurement kit (HY-K0301; Beyotime Institute of Biotechnology, Haimen, China). CD8^+^ T-cells releasing IFN-γ were determined via flow cytometry (FCM), and the amount of IFN-γ produced was measured using the mouse IFN-γ Quantikine ELISA kit (MIF00; R&D Systems, Inc., Minneapolis, MN, USA).

### Tumor assessment

First, 1×10^6^ CT26 cells/100 µl were injected into each C57BL/6 mouse (n=6, male) on the right back. DC vaccines were then administered at 1, 7 and 14 days after injection with cancerous cells. Mice were administered with CT26 lysate-pulsed Ag85A-DCs (Ag85A-DC vaccine), CT26 lysate-pulsed mimic-DCs (mimic-DC vaccine), or CT26 lysate (control) into the tumors. Length, width and height (mm) of the tumor was measured with a caliber every 3 days and the volume of tumors was calculated using the formula as previously ([@b29-etm-0-0-6851]): V (mm^3^)=0.52 × length × width × height. The corresponding tumor weights were measured following sacrifice.

### Statistical analysis

Data are presented as the mean ± standard error of the mean. Significant differences among groups were evaluated by one-way analysis of variance, followed by Tukey\'s post-hoc test using SPSS software 17.0 (SPSS, Inc., Chicago, IL, USA). P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Ag85A-transfected DCs

Transfection of DCs with Ag85A DNA was determined to be successful by RT-qPCR. As indicated in [Fig. 1](#f1-etm-0-0-6851){ref-type="fig"}, Ag85A mRNA levels were significantly upregulated in Ag85A-transfected DCs compared with negative controls.

### Ag85A transfection promotes the expression of primary surface markers in DCs

To fully understand the effects of Ag85A on DCs, the expression of primary surface markers was first evaluated in Ag85A-transfected DCs. FCM results revealed that the Ag85A-transfected DCs exhibited significantly increased expression of MHC class II, CD80 and CD86 compared with the mock-DCs or negative control DCs ([Fig. 2](#f2-etm-0-0-6851){ref-type="fig"}). These findings indicated that Ag85A transfection promotes the expression level of primary surface markers in DCs.

### Ag85A transfection promotes T-cell proliferation

Ag85A-transfected DCs were identified to be more effective in inducing allogeneic T-cell proliferation compared with negative control DCs and mock-DCs. Ag85A-DC-induced T-cell proliferation was significantly increased at 48 and 72 h compared with mock-DCs and negative control DCs ([Fig. 3](#f3-etm-0-0-6851){ref-type="fig"}). These findings suggested that Ag85A-DCs could trigger T-cell activation.

### Ag85A transfection increases tumor-specific cytotoxicity of T-cells in vitro

T-cells incubated with CT26 lysate-pulsed Ag85A-DCs exhibited significantly enhanced cytolytic effects compared with those incubated with mock-DCs ([Fig. 4A](#f4-etm-0-0-6851){ref-type="fig"}). Furthermore, Ag85A-DCs exhibited significantly increased IFN-γ production compared with the CT26 lysate-pulsed mock-DCs and CT26 lysate alone ([Fig. 4B](#f4-etm-0-0-6851){ref-type="fig"}). Furthermore, the proportion of IFN-γ-producing CD8^+^ T-cells was investigated. As indicated in [Fig. 4C](#f4-etm-0-0-6851){ref-type="fig"}, the proportion of IFN-γ^+^ CD8^+^ cells was considerably higher in cells primed by CT26 lysate-pulsed Ag85A-DCs compared with cells primed by CT26 lysate alone or CT26 lysate-pulsed mock-DCs. These data demonstrated the potential of Ag85A-DCs to induce the activation of certain cytotoxic T-cells *in vitro*.

### Intratumorally injected Ag85A-DC vaccine suppresses tumor development in mice

Finally, the effect of Ag85A-DCs on colorectal cancer growth was examined. As depicted in [Fig. 5](#f5-etm-0-0-6851){ref-type="fig"}, mice administered with the Ag85A-DC vaccine had significantly smaller tumor weights and volumes compared with those administered with the mock-DCs vaccine. These findings indicate that the Ag85A-DCs vaccine effectively inhibited tumor growth *in vivo*.

Discussion
==========

The current findings revealed that Ag85A-transfected DCs upregulated the expression of MHC-II, CD80 and CD86. Ag85A-DCs promoted allogeneic T-cell proliferation, elicited stronger activities against CT26 tumor cells and increased IFN-γ production. In addition, treatment with the Ag85A-DCs vaccine considerably suppressed tumor progression in mice. Therefore, it was concluded that Ag85A-transfected DCs enhanced immunity against colorectal carcinoma. The current results provided valuable insights and highlighted the potential use of Ag85A-transfected DC vaccines as an immunotherapeutic strategy for cancer treatment.

DCs are potentially effective for T-cell immunity. DCs primed with antigens migrate to lymphoid tissues to prime T-cells and activate the immune response by expressing co-stimulating and adhesive cell surface molecules. Host APCs play crucial roles in tumor antigen presentation ([@b30-etm-0-0-6851]). Nevertheless, various factors limit APC maturation and penetration into tumor tissues ([@b31-etm-0-0-6851],[@b32-etm-0-0-6851]). A previous study demonstrated that production and maturation of DCs are inhibited by multiple agents in patients with colorectal carcinoma ([@b33-etm-0-0-6851]). In the present study, it was demonstrated that Ag85A-transfected DCs strongly induced expression of primary surface markers, including MHC-II, CD80 and CD86, indicating that Ag85A promoted DC generation and maturation and enhanced anti-tumor immunity.

Ag85A is a key secretory protein in mycobacteria and thus acts as an effective stimulator of cell-regulated immunity ([@b34-etm-0-0-6851],[@b35-etm-0-0-6851]). Reorganized Ag85A DNA was demonstrated to trigger strong immune reactions, leading to dramatic upregulation of Th1 cytokines (IFN-γ and IL-2), which are crucial mediators of immunity. In turn, the Th1 cytokines functioned by stimulating cytotoxic cells and eliminating infected cells ([@b36-etm-0-0-6851]--[@b38-etm-0-0-6851]). In the current study, it was observed that Ag85A-DCs promoted allogeneic T-cell proliferation and increased IFN-γ production. DCs transfected with Ag85A exhibited faster maturation both in terms of phenotype and function. Ag85A-DCs could effectively induce the activation of original T-cells, thereby acting as mediators between the internal and external immunities. Therefore, Ag85A-DCs represent a promising vaccine for immunotherapy of tumors and other diseases.

The application of DC-dependent tumor vaccination is effective as an auxiliary agent to stimulate cancer-specific immunity and represents a promising treatment strategy for cancerous diseases ([@b39-etm-0-0-6851]). Considering the development of drug resistance in late-stage tumor patients subjected to chemotherapy, the current findings contribute to the development of an alternative therapeutic strategy against tumors ([@b40-etm-0-0-6851]). DCs could be incubated with synthetic polypeptides and proteins derived from tumors. Whereas vaccines are developed to target one specific tumor antigen, antigens derived from tumor cell lysates can trigger a wide range of T-cell responses against various tumor-related antigens ([@b41-etm-0-0-6851]). Vaccines containing DCs primed with tumor cell lysates have demonstrated strong potency against various tumor types in both laboratory and clinical settings ([@b42-etm-0-0-6851],[@b43-etm-0-0-6851]). In the current experiments, Ag85A-DCs and mock-DCs incubated with CT26 lysates triggered T-cell activation against certain tumors and induced cytolytic activities targeting CT26 tumor cells. Furthermore, T-cells primed with CT26 lysate-pulsed Ag85A-DCs exhibited increased tumor-specific CTL activities compared with T-cells primed with mock-DCs. Intratumorally injected Ag85A-DC vaccines significantly inhibited tumor development in mice.

In conclusion, the current study demonstrated that Ag85A-DCs promoted DC maturation, triggered the activation of cancer-specific T-cells and promoted anti-tumor cytolytic activities, thereby contributing to tumor growth inhibition. DCs in combination with the Ag85A gene could reinforce anti-colorectal carcinoma immunity. Ag85A-DC vaccines could serve as effective immunity activators and thus contribute to the development of therapies against cancers.

Not applicable.

Funding
=======

This study was supported financially by grants from the National Natural Science Foundation of China (grant no. 31270972) and Characteristic Cross Disciplinary Construction Project of Inner Mongolia University for the Nationalities 'Study on the prevention and therapy of brucellosis of Mongolian Medicine' in 2017 (grant no. MDXK007).

Availability of data and materials
==================================

All data generated or analyzed during this study are included in this article.

Authors\' contributions
=======================

JZ and WG conceived the project, designed and performed the experiments, analyzed the data and wrote the manuscript. LZ performed experiments and analyzed the data. ZG and XJ performed the *in vivo* experiments. CL conceived the project, designed the experiments and revised the manuscript. All authors read and approved the final version of the document.

Ethics approval and consent to participate
==========================================

The animals used in our study were treated in accordance with protocols approved by the Committee on the Ethics of Animal Experiments of China Medical University (Shenyang, China).

Patient consent for publication
===============================

Not applicable.

Competing interests
===================

The authors declare that they have no competing interests.

![Determination of Ag85A mRNA expression levels by RT-qPCR. Ag85A expression in DC 2.4 cells transfected with pc-DNA3.1, DC2.4 plus pcDNA3.1 (mock-DC) or non-transfected DC 2.4 (Con) for 24 h was determined by RT-qPCR. Data are presented as the mean ± standard error of the mean from three independent tests. \*\*P\<0.01 vs. mock-DC group. DC, dendritic cell; Ag85A, antigen 85A; Con, control; RT-qPCR, reverse transcription-quantitative polymerase chain reaction.](etm-16-06-5123-g00){#f1-etm-0-0-6851}

![Ag85A transfection enhances the expression level of primary surface markers in DCs. Expression levels of (A) CD80, (B) CD86 and (C) MHC class II in Ag85ADCs, mock-DCs and controls were assessed via flow cytometry. Data are presented as the mean ± standard error of the mean from three independent tests. \*\*P\<0.01 vs. mock-DC group. DC, dendritic cell; Ag85A, antigen 85A; Con, control; MHC, major histocompatibility complex.](etm-16-06-5123-g01){#f2-etm-0-0-6851}

![Ag85A transfection promotes T-cell proliferation. T-cell proliferation was measured by Cell Counting Kit 8 analysis on days 1, 2 and 3. Data are presented as the mean ± standard error of the mean from three independent tests. \*P\<0.05 vs. mock-DC group. DC, dendritic cell; Ag85A, antigen 85A; Con, control.](etm-16-06-5123-g02){#f3-etm-0-0-6851}

![Ag85A transfection increases tumor-specific cytotoxicity of T-cells *in vitro*. (A) Cytotoxic T-lymphocyte activity was measured by targeting CT26 tumor cells in CT26 lysate-pulsed Ag85A-DCs (Ag85A DC), CT26 lysate-pulsed mock-DCs (mock-DCs) and CT26 lysate (Con) at an effector-to-target ratio of 50:1. (B) IFN-γ production was assessed via ELISA. (C and D) Frequencies of CD8^+^ IFN-γ^+^ T cells were analyzed via flow cytometry. Data are presented as the mean ± standard error of the mean from three independent tests; \*P\<0.05 vs. control group; ^\#^P\<0.05 vs. mock-DC group. DC, dendritic cell; Ag85A, antigen 85A; Con, control; IFN, interferon.](etm-16-06-5123-g03){#f4-etm-0-0-6851}

![Administration of Ag85A-DC vaccine into tumors suppresses tumor development in mice. (A) Images, (B) weights and (C) volumes of resected orthotopic xenograft lab mice at 21 days after administration of tumor cells into the Ag85A-DC vaccine group, mock-DC vaccine group, and CT26 lysate group. Data are presented as the mean ± standard error of the mean, n=6. \*P\<0.05 vs. control; ^\#^P\<0.05 vs. mock-DC vaccine group. DC, dendritic cell; Ag85A, antigen 85A; Con, control.](etm-16-06-5123-g04){#f5-etm-0-0-6851}
